DARE News and Press, Dare Bioscience Inc. From 05/14/24

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil b...

2024-05-13 17:35:36 ET Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. ( OXLC ) Capital Southwest Corporation ( CSWC ) Seadrill Limited ( SDRL ) Nu Holdings Ltd. ( NU ) Canoo ( GOEV ) Read the full articl...

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to review its financial results for the qua...

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub , a regional hub of ARPANET-H , a nationwide health innovation network launched by ...

2024-04-30 08:43:05 ET More on Dare Bioscience Dare Bioscience FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dare Bioscience Financial information for Dare Bioscience Read the full artic...

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50% of the future payments otherwise payable to XOMA Tra...

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contrace...

2024-03-28 20:47:08 ET Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Conference Call March 28, 2024, 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting Officer Conference Call Participants ...

2024-03-28 08:11:27 ET More on Dare Bioscience Dare Bioscience FY 2023 Earnings Preview Daré Bioscience announces executive team changes Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dare Bioscience Financ...